Modifying the antigen-immunization schedule improves the variety of monoclonal antibodies obtained from immune-phage antibody libraries against HIV-1 Nef and Vif

Journal of Bioscience and Bioengineering

Volumn 111, Issue 5, 2011, Pages 597-599

  Yoshikawa, Mai ^a   Mukai, Yohei ^a   Tsunoda, Shin Ichi ^b   Tsutsumi, Yasuo ^a,b   Yoshioka, Yasuo ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Antibody library; Antibody therapy; Drug delivery; HIV 1; Immunization; Monoclonal antibody; Phage display system; Targeting

Indexed keywords

ANTIBODY LIBRARY; ANTIBODY THERAPY; HIV-1; PHAGE DISPLAY SYSTEM; TARGETING;

ALLERGIES; ANTIGENS; CLONING; DRUG DELIVERY; IMMUNIZATION; LIBRARIES; MERGERS AND ACQUISITIONS; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE;

DISPLAY DEVICES;

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MONOCLONAL ANTIBODY; NEF PROTEIN; VIF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LIBRARY; ARTICLE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GENE LIBRARY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MOLECULAR CLONING; MOUSE; NONHUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; CLONING, MOLECULAR; FEMALE; HIV ANTIBODIES; HIV-1; IMMUNIZATION SCHEDULE; MICE; MICE, INBRED BALB C; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDE LIBRARY; SINGLE-CHAIN ANTIBODIES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79954938975     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2010.12.025     Document Type: Article

References (11)

1. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
2. Rojas G., Almagro J.C., Acevedo B., Gavilondo J.V. Phage antibody fragments library combining a single human light chain variable region with immune mouse heavy chain variable regions. J. Biotechnol. 2002, 94:287-298.
3. Honjo T., Habu S. Origin of immune diversity: genetic variation and selection. Annu. Rev. Biochem. 1985, 54:803-830.
4. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23:1147-1157.
5. Griffiths A.D., Duncan A.R. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 1998, 9:102-108.
6. Nieri P., Donadio E., Rossi S., Adinolfi B., Podesta A. Antibodies for therapeutic uses and the evolution of biotechniques. Curr. Med. Chem. 2009, 16:753-779.
7. Richter S.N., Frasson I., Palu G. Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy. Curr. Med. Chem. 2009, 16:267-286.
8. Fackler O.T., Alcover A., Schwartz O. Modulation of the immunological synapse: a key to HIV-1 pathogenesis. Nat. Rev. Immunol. 2007, 7:310-317.
9. Imai S., Mukai Y., Nagano K., Shibata H., Sugita T., Abe Y., Nomura T., Tsutsumi Y., Kamada H., Nakagawa S., Tsunoda S. Quality enhancement of the non-immune phage scFv library to isolate effective antibodies. Biol. Pharm. Bull. 2006, 29:1325-1330.
10. Lo A.S., Zhu Q., Marasco W.A. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb. Exp. Pharmacol. 2008, 181:343-373.
11. Worn A., Auf der Maur A., Escher D., Honegger A., Barberis A., Pluckthun A. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J. Biol. Chem. 2000, 275:2795-2803.